NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Matias Arrupe: The Value of Lipoprotein(a) in Reclassifying Cardiovascular Risk
Matias Arrupe/LinkedIn
Nov 19, 2025, 13:39

Matias Arrupe: The Value of Lipoprotein(a) in Reclassifying Cardiovascular Risk

Matias Arrupe, Cardiologist at CardioInnova Medical Research, shared on LinkedIn:

”Reclassifying Cardiovascular Risk with a Simple Test: The Value of Lipoprotein(a)

New insights from a pilot study in Spain highlight how Lipoprotein(a) (Lp(a)) can uncover hidden cardiovascular risk even in patients classified as low or moderate risk.

Study Overview:

Participants: 140 adults (62.9% women, average age 54.3)
Initial Classification: Low (41.4%) or Moderate (58.6%) cardiovascular risk (SCORE2)
Intervention: Lp(a) measurement
Outcome: Reclassification based on Lp(a) >50 mg/dL

Key Findings:

  • 22.1% had Lp(a) >50 mg/dL
  • 22.6% of low-risk individuals were reclassified to moderate risk
  • 77.4% of moderate-risk individuals were reclassified to high risk
  • 61.4% of the cohort became eligible for statin therapy

Why Lp(a) Matters:

  • Lp(a) levels are genetically determined in over 80% of individuals.
  • One single measurement is sufficient to assess lifetime cardiovascular risk.
  • Elevated levels are not affected by age or lifestyle.
  • Lp(a) >180 mg/dL may confer a risk similar to familial hypercholesterolemia.

Clinical Implications:

  • Most individuals with elevated Lp(a) would otherwise remain undiagnosed.
  • Measuring Lp(a) could shift therapeutic decisions significantly.
  • Potential for family screening due to hereditary nature.

Challenges and Future Steps:

  • Lp(a) is rarely measured despite guidelines recommending at least one lifetime assessment.
  • No targeted therapies to lower Lp(a) below 50 mg/dL, but PCSK9 inhibitors show promise.
  • This pilot study may lead to routine inclusion of Lp(a) in cardiovascular screening protocols.

This research reinforces the necessity of moving toward personalized risk assessment in cardiovascular care.”

Title: Reclassification of Low or Intermediate Cardiovascular Risk by Determining Lipoprotein(a) Levels

Authors: Alberto Cordero, José Ma Salinas, María Amparo Quintanilla, José Ma López-Ayala, Álvaro Blasco, Emilio Flores

Matias Arrupe

Read the full article here.

Stay informed with Hemostasis Today.

Alberto Cordero Álvaro Blasco cardiovascular risk Emilio Flores Family Screening Hemostasis Today Hypercholesterolemia José Ma López-Ayala José Ma Salinas Lipoprotein María Amparo Quintanilla Matias Arrupe PCSK9 inhibitors
NewsFeed